Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer

Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer

Background Toll-like receptor (TLR) agonists and radiation therapy hold promise for cancer immunotherapy. We conducted a phase I/II trial combining topical imiquimod (IMQ, a TLR-7 agonist) and local radiotherapy (RT) in patients with metastatic breast cancer accompanied by longitudinal transcription...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ping Jin, Xiaochun Li, Francesco Marincola, Ena Wang, Sandra Demaria, Davide Bedognetti, Darawan Rinchai, Sylvia Adams, Yelena Novik, Ruth Oratz, David Stroncek, Judith Goldberg, Silvia Chiara Formenti, Maria Fenton-Kerimian, Pascale G Levine
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e011173.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Novel Application Paradigm for Tumor In-Situ Vaccination: Synergistic Effects of TLR7/8 Agonists and Radiotherapy
by: Xiaolin YOU, et al.
Published: (2025-07-01)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
by: Jinghua Sun, et al.
Published: (2012-01-01)

De novo design of protein minibinder agonists of TLR3
by: Chloe S. Adams, et al.
Published: (2025-01-01)

Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway
by: Xuejiao Han, et al.
Published: (2025-07-01)

A Chemically Defined TLR3 Agonist with Anticancer Activity
by: Julie Le Naour, et al.
Published: (2023-12-01)

TLR4 Agonist Monophosphoryl Lipid A Alleviated Radiation-Induced Intestinal Injury
by: Jiaming Guo, et al.
Published: (2019-01-01)

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
by: Aashna Jassal, et al.
Published: (2024-11-01)

Single atom engineering for radiotherapy-activated immune agonist prodrugs
by: Zexuan Ding, et al.
Published: (2025-07-01)

Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer
by: Seyedeh A. Najibi, et al.
Published: (2025-05-01)

Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors
by: Haiting Xu, et al.
Published: (2025-01-01)

Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology
by: Francesca A. Mercuri, et al.
Published: (2024-12-01)

TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-κB/HIF-1α Loop in Human Epithelial Ovarian Cancer
by: Bin Zhao, et al.
Published: (2022-01-01)

Multivalent COBRA Hemagglutinin and Neuraminidase Influenza Vaccines Adjuvanted with TLR9 Agonist CpG 1018
by: Pedro L. Sanchez, et al.
Published: (2025-06-01)

The Effect of TLR9 Agonist CpG Oligodeoxynucleotides on the Intestinal Immune Response of Cobia (Rachycentron canadum)
by: Omkar Byadgi, et al.
Published: (2014-01-01)

Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies
by: Meggie Danielson, et al.
Published: (2024-12-01)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
by: Craig L Slingluff, et al.
Published: (2021-05-01)

Human-augmented large language model-driven selection of glutathione peroxidase 4 as a candidate blood transcriptional biomarker for circulating erythroid cells
by: Bishesh Subba, et al.
Published: (2024-10-01)

Gut microbiota-derived GlcNAc-MurNAc is a TLR4 agonist that protects the host gut
by: Chenyu Li, et al.
Published: (2025-07-01)

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine
by: Michael W. Crawford, et al.
Published: (2025-07-01)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.
by: Brian Moldt, et al.
Published: (2022-04-01)

Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice
by: Zhangping Huang, et al.
Published: (2025-06-01)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
by: Zhaoming Wang, et al.
Published: (2020-10-01)

Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
by: Jarosz-Biej Magdalena, et al.
Published: (2025-02-01)

Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity
by: Yarong Zeng, et al.
Published: (2025-07-01)

All-Natural Gelatin-Based Nanoemulsion Loaded with TLR 7/8 Agonist for Efficient Modulation of Macrophage Polarization for Immunotherapy
by: Ritabrita Goswami, et al.
Published: (2024-09-01)

Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
by: George J Weiner, et al.
Published: (2021-06-01)

Correction: Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
by: Magdalena Jarosz-Biej, et al.
Published: (2025-05-01)

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
by: Maud Charpentier, et al.
Published: (2023-12-01)

Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy
by: Qian Zeng, et al.
Published: (2025-06-01)

TLR3 Agonist Amplifies the Anti-Inflammatory Potency of ADSCs via IL-10-Mediated Macrophage Polarization in Acute Pancreatitis
by: Jianxing Liu, et al.
Published: (2024-01-01)

Adjuvantation of Kyasanur Forest Disease vaccine with TLR9 agonist CpG adjuvant enhances immunological efficacy and potency of the vaccine
by: Chandranaik B. Marinaik, et al.
Published: (2025-01-01)

Adjuvantation of Kyasanur Forest Disease vaccine with TLR9 agonist CpG adjuvant enhances immunological efficacy and potency of the vaccine.
by: Chandranaik B Marinaik, et al.
Published: (2025-01-01)

TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity
by: Shuting Wu, et al.
Published: (2025-01-01)

Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
by: Anita Milicic, et al.
Published: (2012-01-01)

Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy in hormone-dependent cancers
by: Rosario Garcia-Campelo, et al.
Published: (2025-05-01)

A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration
by: Ryunosuke Oyama, et al.
Published: (2025-01-01)

In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression
by: Yan Xu, et al.
Published: (2025-05-01)

Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects
by: Chao Hu, et al.
Published: (2025-07-01)

C3-Liposome Delivery of MUC1 Peptide and TLR Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth Differences
by: Shahab Soltani, et al.
Published: (2025-04-01)

Author Correction: SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate
by: Ernesto Luna, et al.
Published: (2025-02-01)